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salmeterol/fluticasone, beclametasone/formoterol, budesonide/formoterol (free 
adjustable combination) and conventional best practice. METHODS: For 
construction of pharmacoeconomic model a set of comparative randomised 
controlled trials for each therapeutic alternative were identified. From them data 
on clinical effectiveness in form of asthma exacerbations avoided for 1 patient-
year were extracted. The analysis was conducted from the perspective of 
Russian health care system. Respectively the cost of the following resources was 
accounted: alternative compared, concomitant pharmacotherapy, cost of 
hospitalizations, cost of ambulkatory visits. Analysis was performed in the form 
of cost-effectiveness analysis the exacerbation prevented being the measure of 
effectiveness. RESULTS: The data of the research illustrates that 
budesonide/formoterol maintenance and reliever therapy for asthma patients 
provides a significant health improvement from the perspective of preventing 
exacerbations. Simultaneosly budesonide/formoterol maintenance and reliever 
therapy demonstrates better cost-effectiveness than alternatives compared. The 
CER index in relation to cost of asthma control during the year (absence  
of exacerbations) for budesonide/formoterol maintenance and reliever therapy 
was 147785 rub. respective figures for salmeterol/fluticasone, beclametasone/ 
formoterol, budesonide/formoterol (free adjustable combination) and 
conventional best practice were 383622 rub., 169245 rub., 227592 rub., 219233 
rub., respectively. CONCLUSIONS: Budesonide/formoterol fixed combination for 
maintenance and reliever therapy turned to be cost-effective therapeutic 
alternative for asthma control in adult patients in conditions of Russian health 
care system.  
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ECONOMIC ASSESSMENT OF GEMIFLOXACIN FOR THE MANAGEMENT OF 
ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS IN MEXICO  
Galindo-Suárez RM1, Salinas-Escudero G2, Muciño-Ortega E1 
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OBJECTIVES: Acute exacerbations of chronic bronchitis (AECB) are a leading 
cause of morbi-mortality and medical resources consumption. This study  
was aimed to estimate the economic and health consequences of first line 
antibiotics in the management of AECB and it´s recurrences, under the setting of 
a representative Mexican health care institution. METHODS: Two models  
were developed: a decision tree for acute events (tree month horizon) and a two-
state, one-quarter cycle Markov for recurrences (one year horizon). The 
competing alternatives (listed in the national formulary) were: moxifloxacin 400 
mg/day, levofloxacin 500 mg/day, ceftriaxone 1000 mg/day, clarithromycin 1000 
mg/day, cefuroxime 1000 mg/day and, not listed in the national formulary, 
gemifloxacin 320 mg/day. The clinical success rate and months free of 
recurrences (effectiveness measures) were extracted from international 
literature. Resource use was extracted from 117 clinical files (adult patients) 
treated at Instituto Mexicano del Seguro Social (IMSS).The cost of antibiotics 
were extracted from IMSS´s sources (except of gemifloxacin, provided by the 
manufacturer); the unit cost of physician visits, diagnostic tests, emergency 
room, in-patient, intensive care unit were the official for IMSS. Costs are 
expressed in 2012 U$. One-way sensitivity analysis was performed. RESULTS: 
The clinical success rates were between 97.5% (gemifloxacin) and 83.1% 
(cefuroxime), the costs per patient-per AECB were proportional: $3,375.6 
(gemifloxacin) and $4825.1% (cefuroxime), gemifloxacin dominated progressively 
ceftriaxone, moxifloxacin, levofloxacin, clarithromycin and cefuroxime. 
Regarding AECB recurrences, clarithromycin represented the highest cost and 
lowest time free of recurrence: $8198.99 and 10.28 months, respectively, whereas 
gemifloxacin represented the opposite: $3,325.73 and 11.015 months, 
respectively. The length of stay were between 6.22 (gemifloxacin) and 10.3 days 
(cefuroxime). The results were robust to +10% acquisition cost, +5% adverse 
events incidence and -5% clinical success rate for gemifloxacin. CONCLUSIONS: 
At IMSS setting, gemifloxacin is an alternative that would promote savings in the 
treatment of AECB and it´s recurrences.  
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LONG-TERM HUMIDIFICATION THERAPY IMPROVES QUALITY OF LIFE AND IS 
COST EFFECTIVE FOR PATIENTS WITH COPD OR BRONCHIECTASIS  
Milne R1, Hockey H2 
1University of Auckland, Auckland, New Zealand, 2BiometricsMatters, Hamilton 3216, New 
Zealand  
OBJECTIVES: To evaluate the cost effectiveness of long-term therapy with high flow 
humidified air supplemented with oxygen as required at 37°C delivered through 
nasal cannulae (long term humidification therapy; LTHT) for patients with 
moderate or severe COPD or bronchiectasis. METHODS: The source was a 12-month 
clinical trial showing that LTHT at a mean duration of 1.6 hours per day reduced 
exacerbation days and improved quality of life assessed by the St. George’s 
Respiratory Questionnaire compared to usual care alone. Resources included the 
LTHT intervention equipment and consumables, relevant hospital admissions, 
general practitioner consultations, Emergency Care presentations and 
pharmaceuticals. Details of consultations and medication usage were obtained 
from patient diaries and hospital admissions from retrospective administrative 
records. Utility values were obtained indirectly from the St Georges Respiratory 
Questionnaire using a published algorithm. The ICUR was estimated over the 
lifetime of the device (5 years) using the bootstrap method with 5000 replications. 
Future costs and benefits were discounted at 3.5% per annum. RESULTS: The 
incremental health state utility over 12 months was estimated at +0.084 (95% CI 
0.003-0.165). Annual costs excluding the intervention were NZ$2329 (95%CI $1249, 
$3409) for the treatment group and NZ$3477 ($712, $6241) for the control group 
(nsd). With the LTHT intervention costed at $10,461 over the lifetime of the device (5 
years) the cost per QALY was NZ$15,615 (95%CI $15,521, $15,709). At a willingness to 
pay (WTP) threshold of NZ$30,000, the probability of LTHT being cost effective was 
89% and at a WTP threshold of $20,000 it was 71%, ranging from 64% to 77% as the 
5-year cost of LTHT equipment and running costs was varied by ±20%. 
CONCLUSIONS: Long term humidification therapy for moderate to severe COPD or 
bronchiectasis is as cost effective as most new pharmaceuticals that are 
reimbursed by the New Zealand government.  
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SECOND-LINE THERAPY IN CHILDREN WITH ASTHMA IN COLOMBIA:  
AN ECONOMIC EVALUATION TO INFORM THE NATIONAL GUIDELINE  
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INTRODUCTION: Childhood asthma is a major public health problem in 
Colombia as in many other countries. In patients entering the second line 
therapy, options in the 5-11 years old category are increase corticosteroids, add 
LABA or add LTRA. In under five years old adding LABA is not an option. There 
are differences in cost and efficacy between these options, to address this issue 
an economic evaluation was done in the context of the National Colombian 
Clinical Practice Guidelines Programme in collaboration with the Colombian 
Pediatric Pneumonology Association. OBJECTIVES: To evaluate the cost 
effectiveness of the second line asthma therapy options in pediatric patients in 
Colombia. METHODS: A Markov model was developed including the following 
health states: controlled asthma, uncontrolled asthma, ambulatory exacerbation, 
exacerbation with hospitalization and therapeutic failure. A restringed social 
perspective was used (health system + out of pocket expenses) with a 3 months 
time horizon. Transition probabilities and utility estimates were derived from 
international literature and validated by a Delphi panel with local Colombian 
experts. Costs were provided by the Colombian MoH. A deterministic and 
probabilistic sensitivity analysis was performed. RESULTS: The LTRA option was 
dominated, being more expensive and less efficacious than increasing 
corticosteroids in both age categories. In the 5-11 years old the ICER comparing 
LABA with corticosteroids was 4.366.343 Colombian pesos (COP) per quality 
adjusted life week (QALW) gained. This ICER is far above the 634.000 COP per 
QALW estimated for a 3 GDP threshold. In the sensitivity analysis these results 
probed to be robust being necessary a 4.400.000 COP per QALW of willingness to 
pay for the LRTA option to start being cost effective. CONCLUSIONS: Increasing 
corticosteroids was the most cost effective option in asthmatic pediatric 
population in Colombia compared to LABA, being LRTA dominated or far above 
the Colombian thresholds.  
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ASSESSMENT OF ADHERENCE TO INHALED CORTICOSTEROID TREATMENT FOR 
ASTHMA: A CROSS-SECTIONAL STUDY FROM DELHI, INDIA  
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OBJECTIVES: Despite the known importance of regular use of inhaled 
corticosteroids (ICS) for asthma control, there is a dearth of adherence literature 
from India. The study aims were to (i) evaluate patients’ self-reported adherence 
to ICS therapy, (ii) identify possible reasons for non-adherence, and (iii) identify 
possible correlations between ICS adherence, medicine beliefs and socio-
demographic factors of asthma patients. METHODS: Adults with previously 
diagnosed asthma (n=200) presenting to the emergency room (March 2009-
December 2009) of a public chest hospital in Delhi for asthma exacerbation 
completed an interviewer-administered questionnaire on socio-demographics, 
clinical history, self-reported adherence, beliefs about causes of disease, 
medicine beliefs and medication adherence after stabilization of their condition. 
RESULTS: Study sample had 51.5% patients in the age group of 30-40 years, 54.0% 
females, 10.0% illiterate, and 62.5% patients earning less than INR 10,000/month 
($185/month). The mean duration of registration with the study hospital was 
5.4±4.4 years and all were prescribed ICS treatment. Self-report on adherence: 
49% took medicines even without symptoms; 91.0% reported they forgot to take 
their medicine “some or lot of times”; 84.0% avoided medicines “some of the 
times”. Important reasons for avoiding medicines were no symptoms (59.5%), 
cost (34.5%), fear of getting dependent (29%), side effects (17%) and social 
inhibition (14.5%). Correlation between self-reported adherence and 
demographic factors, such as age, sex, education and income was calculated. 
The commonly endorsed causes for asthma were pollution (33.5%), poor medical 
care in the past (15.5%), heredity (8.5%), cold climate (7.5%), and diet (5.5%). Non-
adherent behaviors were associated with doubts about the necessity of 
medication and concerns about its potential side effects with long-term use (r=-
0.299, p<0.001). CONCLUSIONS: Adherence to ICS therapy is poor and many 
factors modulate adherence to therapy. These findings lend preliminary support 
for an extended self-regulatory model of treatment adherence, which 
incorporates beliefs about treatment.  
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OBJECTIVES: Satisfaction with a medication can be an important driver of 
adherence; satisfaction also can be related to both medication administration 
and effectiveness. Our objective is to explore the association between medication 
adherence and satisfaction and the administration characteristics of respiratory 
medications – e.g., inhaled, oral, combinations - used for chronic obstructive 
pulmonary disease (COPD.) METHODS: Data were obtained from the 2012 U.S. 
National Health and Wellness Survey (NHWS). The NHWS is an annual Internet-
based survey, using stratified random sampling to ensure demographic 
representativeness of the adult U.S. population. Respondents reporting diagnosis 
with COPD, emphysema, and/or chronic bronchitis and taking an inhaled or oral 
prescription medication for their condition were included. Treatment groups 
were compared on demographics, treatment patterns, satisfaction and 
adherence (using the Morisky Medication Adherence Scale [MMAS]-8), using Chi-
square and ANOVA tests as appropriate. RESULTS: The 1,979 respondents were 
grouped as follows: 1.3% on a pill (leukotriene modifier), 18% long-acting 
bronchodilator inhaler (LABD) only, 20.4% on short-acting bronchodilator inhaler 
(SABD) only, 0.8% on pill combined with another non-SABD inhaler, 0.9% on 
pill+SABD, 6.1% inhaler combination (non-SABD), 27.9% inhaler combination 
with SABD, 0.9% on triple therapy (non-SABD) and 23.8% on triple therapy that 
includes SABD. Patients on pill only (n=25) medication were younger, reported 
lower disease severity and were less frequently current or former smokers 
versus other treatment groups (all p<0.05). Among pill-only patients, 60% were 
very/extremely satisfied with their treatment. Pill-only patients were 
significantly more adherent to their medication, compared with pill and inhaler 
combination and triple therapy (excluding SABD) groups, all p<0.05. Mean 
satisfaction and adherence scores were correlated at r=-0.131, p<0.0001, 
indicating that higher satisfaction is associated with better adherence to 
treatment. CONCLUSIONS: Oral medications have the potential to improve 
adherence and satisfaction in COPD treatment, but further research with larger 
samples is needed.  
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IMPACT OF SMOKING CESSATION AGENTS ON THE MENTAL HEALTH STATUS  
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OBJECTIVES: Varenicline and bupropion are commonly recommended 
pharmacotherapies for smoking cessation. Post marketing reports suggest that 
bupropion and varenicline are associated with an increased incidence of 
psychiatric disturbances. However, pre-existing psychiatric conditions and lack 
of cigarettes (nicotine) confound the association between smoking cessation 
agents (SCA) and psychiatric disturbances. The aim of the study was to 
determine the impact of SCA on the mental health status. METHODS: Data were 
from the 2006-2010 Medical Expenditure Panel Survey. Adults with new episodes 
of varenicline or bupropion, defined as current use of one of these agents 
without prior use of any SCA agents in the previous round, were identified. The 
main outcome was the mental component summary (MCS) scores derived from 
the mental health component of SF-12v2. The MCS scores of SGA agent users 
were compared to that of current smokers and adults who quit smoking without 
any SCA use. Linear regression was used to adjust for sociodemographic 
characteristics, pre-existing psychiatric conditions, and medical comorbidities. 
RESULTS: There were 117 new episodes of varenicline use, 426 new episodes of 
bupropion use, 1138 subjects who quit smoking without any SCA and 9178 
current smokers. Compared to current smokers, varenicline use was associated 
with a statistically as well as clinically insignificant change in the MCS score 
(0.20) [p>0.05] while bupropion use was associated with a significant decrease in 
the MCS score (-4.18) [p<0.01]. Subjects who quit smoking with any SCA use were 
associated with a clinically insignificant increase in the MCS score (1.39) [p<0.01]. 
The presence of pre-existing psychiatric conditions was associated with a 
significant decrease in the MCS score [-4.33] (p<0.01). CONCLUSIONS: Varenicline 
is associated with an insignificant change in mental health status, compared 
with current smokers. The study supports the use of varenicline as first line 
therapy for smoking cessation.  
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OBJECTIVES: Poor asthma control is associated with deleterious clinical  
and economic outcomes. This research examined the association between 
asthma control and health-related quality of life (HRQL). METHODS: The 
Observational Study of Asthma Control and Outcomes (OSACO) was a 
prospective survey of asthma patients in Kaiser Colorado in 2011-2012. Patients 
were mailed a survey three times in one year. The survey included the Asthma 
Control Questionnaire (ACQ-6), mini-Asthma Quality of Life Questionnaire 
(AQLQ), EQ-5D and questions on asthma exacerbations and adherence. A subset 
received spirometry testing and completed the ACQ-7 at National Jewish Health. 
Regression analyses examined the impact of asthma control (ACQ) on EQ-5D, 
mini-AQLQ and VAS scores controlling for age, gender, family income level, race, 
educational attainment and ethnicity. The functional relationship between 
asthma control and each outcome was estimated. Different cut-points of the 
ACQ were explored (above-below .75, 1.0, 1.5; categories 0-1, 1-2, etc.; 0-0.75, 0.75-
1.5, etc.). RESULTS: There were 2,683 respondents to the first survey of whom 
596 completed spirometry. The relationship between ACQ scores and HRQL was 
statistically significant and linear. Higher ACQ scores corresponded with lower 
HRQL for all instruments. Each one-point increase in ACQ6 (ACQ7) score was 
associated with the following changes: -0.064 EQ-5D (-0.069 for ACQ7), -5.985 VAS 
(-4.5 for ACQ7) and -1.05 mini-AQLQ (-1.03 for ACQ7). Different cut-points 
resulted in slightly different magnitude decrements but similar directionality for 
each HRQL instrument. CONCLUSIONS: Poor asthma control is highly correlated 
with decreased HRQL as measured by the mini-AQLQ and the EQ-5D.  
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OBJECTIVES: To examine smokers’ beliefs in potential effectiveness of available 
smoking cessation interventions in Jordan. METHODS: A cross-sectional survey-
based study in a convenient sample of willing adults in Amman, Jordan (n=600). 
Participants who reported using a cigarette or a waterpipe to smoke tobacco in 
the past 30 days were considered current smokers and included in further 
analysis. Cigarette and waterpipe smoking were being analyzed separately with 
two outcome variables for each smoking behavior: 1) believing smoking 
cessation medications are helpful in quitting versus not, and 2) believing 
educational programs/counseling by health care providers are helpful versus not. 
Multivarite logistic regression was used to determine participant characteristics 
associated with the defined outcomes. RESULTS: More smokers believed in the 
effectiveness of educational program as compared to the medications. Cigarette 
smokers who find it hard to abstain from smoking where they are not allowed to 
were more likely to believe cessation medications are helpful (OR=1.79, 
95%CI=1.01–3.15). Cigarette smokers with a lower education level (OR=0.33, 
95%CI=0.14–0.78), with a father who smokes (OR=0.39, 95%CI=0.21–0.75), or who 
tried cigar smoking in the past month (OR=0.39, 95%CI=0.18–0.86) were less likely 
to think educational programs are helpful. Waterpipe smokers who were older 
were less likely to believe cessation medications (OR=0.41, 95%CI=0.17–0.99) and 
educational programs (OR=0.38, 95%CI=0.18–0.80) are useful. Males (OR=6.07, 
95%CI=1.82–20.26) were more likely to believe cessation medications are helpful. 
Waterpipe smokers who have used cigar before (OR=0.16, 95%CI=0.05–0.51) were 
less likes to perceive the effectiveness of medication. On the other hand, whose 
father is also a waterpipe smoker (OR=0.39, 95%CI=0.17–0.89) was less likely to 
believe educational programs are helpful. CONCLUSIONS: Understanding these 
opinions from a smoker’s perspective is important in designing culturally 
appropriate interventions to help smokers quit.  
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TRANSLATION AND VALIDATION PROCESS FOR THE MINNESOTA NICOTINE 
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OBJECTIVES: To translate the Minnesota Nicotine Withdrawal Scale (MNWS) to 
Malay language and evaluate the psychometric properties of translated version. 
METHODS: A cross sectional design was used to elaborate the study data. Adult 
smokers who attend the Quit Smoking Clinic in Penang General Hospital at 
Penang State, Malaysia were included in the study. The original scale was 
translated into Malay version following the standard guidelines proposed for 
translation studies. The reliability and validity of Malay version scale was 
evaluated based on the data collected from 133 participants. Cronbach’s alpha 
coefficient was calculated to assess the reliability. In order to assess the validity 
of the scale, Factor analysis and convergent validity was employed to validate 
the psychometric properties of the scale. RESULTS: The Malay version of MNWS 
has an excellent reliability with an internal consistency was measured by total 
Cronbach’s alpha of 0.91. The test-retest reliability for the scale were presented 
an excellent reliability and stability of the translated scale with Spearman’s Rank 
Correlation Coefficient, r=0.876 (P<0.001). In addition, There was a significant 
positive correlation between carbon monoxide level, FTND total score and 
number of cigarettes smoked per day with MNWS total score (r=0.72, r=0.68 and 
r=0.68, P<0.001; respectively). A principal components analysis with orthogonal 
rotation yielded a uni-dimensional model which includes all the items of MNWS. 
CONCLUSIONS: The Malay version of MNWS is reliable and a valid measure for 
withdrawal symptoms as well as the smoking urge and it is applicable for 
clinical practice and research study.  
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OBJECTIVES: The objective of this study was to identify and compare predictors 
of smoking cessation attempts and successful smoking cessation. METHODS: A 
cross-sectional study using the 2009 U.S. Behavioral Risk Factor Surveillance 
System (BRFSS) survey database was performed. Current smokers (69,583) and 
ex-smokers who quit smoking during the previous year (8,489) were identified 
from BRFSS to compose study population. Multiple logistic regression was used 
to compare the socio-demographic characteristics and smoking-related disease 
status (1) between smokers who initiated smoking cessation attempts and those 
